Top 10 Companies in the (2-Chloroethyl)benzene (CAS 622-24-2) Market (2026): Market Leaders Powering Global Chemical Supply

MARKET INSIGHTS

Global (2-Chloroethyl)benzene (CAS 622-24-2) market size was valued at USD 85.4 million in 2025. The market is projected to grow from USD 89.2 million in 2026 to USD 138.7 million by 2034, exhibiting a CAGR of 5.6 % during the forecast period.

(2‑Chloroethyl)benzene, also known as benzyl chloride ethyl analog or phenethyl chloride, is an organochlorine compound with the molecular formula C₆H₇Cl. It is a colorless to pale yellow liquid primarily used as a chemical intermediate in the synthesis of pharmaceuticals, agrochemicals, and specialty chemicals. Its reactive chloroethyl group makes it a valuable building block in organic synthesis, particularly in the production of active pharmaceutical ingredients (APIs) and fine chemical formulations.

The market is driven by steady demand from the pharmaceutical and agrochemical sectors, where the compound serves as a critical precursor in synthesis pathways. However, regulatory scrutiny surrounding chlorinated organic compounds continues to shape sourcing and handling practices across the supply chain. Key producers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and various specialized fine chemical manufacturers across China, India, and Europe.

(2‑Chloroethyl)benzene (CAS 622‑24‑2) Market – View in Detailed Research Report

Top 10 Companies in the (2‑Chloroethyl)benzene (CAS 622‑24‑2) Market

1. PharmaBlock Sciences (China)

   Headquarters: Shanghai, China
   Key Offering: High‑purity pharmaceutical intermediates, including (2‑Chloroethyl)benzene

   PharmaBlock Sciences has positioned itself as a primary supplier of fine‑chemical intermediates for API development. Leveraging a vertically integrated production line, the company maintains tight control over raw‑material sourcing and process optimization, which translates into consistent product quality and reduced lead times. The firm’s emphasis on stringent quality management systems—ISO 9001 and GMP compliance—has earned it a reputation among contract manufacturers seeking reliable partners for complex syntheses.

   Sustainability & Growth Initiatives: The company has invested in closed‑loop solvent recovery systems and low‑energy halogenation units, reducing waste by 18 % and aligning with global ESG targets.

   • Advanced halogenation reactors with real‑time monitoring
   • ISO 9001, GMP, and REACH‑certified production lines
   • Strategic partnership with leading API developers in Asia
   • Continuous process improvement program reducing batch variability

2. Capot Chemical Co., Ltd. (China)

   Headquarters: Guangzhou, China
   Key Offering: Bulk (2‑Chloroethyl)benzene and specialty grades for agrochemicals

   Capot Chemical’s manufacturing footprint spans three dedicated plants, enabling high‑volume production while maintaining strict purity standards. The company’s integrated supply chain—from benzene procurement to final product packaging—has minimized bottlenecks and kept inventory turnover above 12 months.

   Sustainability & Growth Initiatives: Capot has implemented a zero‑liquid‑discharge policy and is exploring bio‑based feedstock alternatives to reduce its carbon footprint.

   • Large‑scale batch reactors with automated safety interlocks
   • ISO 14001 and REACH compliance across all sites
   • Collaborations with agricultural research institutes for new pesticide formulations
   • Investment in energy‑efficient HVAC systems

3. A. B. Enterprises (India)

   Headquarters: Mumbai, India
   Key Offering: Custom synthesis of (2‑Chloroethyl)benzene for niche applications

   Operating from a 10‑acre campus, A. B. Enterprises has carved out a niche by providing tailored synthesis services to pharmaceutical R&D labs and specialty chemical firms. The company’s flexible batch sizes and rapid turnaround make it a preferred partner for pilot‑scale projects.

   Sustainability & Growth Initiatives: A. B. Enterprises has adopted green chemistry principles, including solvent‑free reactions and catalytic halogenation, cutting solvent consumption by 25 %.

   • Modular synthesis units supporting scale‑up
   • ISO 9001 and ISO 14001 certifications
   • Strategic alliances with Indian pharma clusters
   • Continuous improvement program focused on waste minimization

4. Tokyo Chemical Industry Co., Ltd. (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: Specialty (2‑Chloroethyl)benzene grades for fine chemicals and fragrance intermediates

   Tokyo Chemical Industry’s flagship plant employs state‑of‑the‑art halogenation technology, enabling the production of ultra‑pure intermediates for fragrance and cosmetic applications. The firm’s strong emphasis on safety and compliance has earned it a strong foothold in the Japanese market and export contracts to the EU.

   Sustainability & Growth Initiatives: The company is piloting a catalytic hydrogenation route to reduce chlorine usage and is actively pursuing LEED certification for its new facility.

   • High‑purity production lines with real‑time quality analytics
   • ISO 9001, ISO 14001, and REACH compliance
   • Collaborations with fragrance houses for novel scent profiles
   • Investment in renewable energy sources for plant operations

5. Oakwood Chemical (USA)

   Headquarters: San Francisco, USA
   Key Offering: Research‑grade (2‑Chloroethyl)benzene for API development

   Oakwood Chemical serves a predominantly R&D‑focused clientele, providing high‑purity intermediates with rapid delivery. The company’s flexible contract‑manufacturing model allows it to support small‑batch, high‑value projects typical of emerging biotech firms.

   Sustainability & Growth Initiatives: Oakwood has introduced a closed‑loop solvent recovery system and is exploring biobased halogenation catalysts.

   • Custom synthesis capabilities for niche APIs
   • ISO 9001 and GMP compliance
   • Partnerships with university research labs
   • Ongoing process optimization to reduce energy consumption

6. Hebei Guanlang Biotechnology Co., Ltd. (China)

   Headquarters: Shijiazhuang, China
   Key Offering: Bulk (2‑Chloroethyl)benzene for agrochemical intermediates

   Hebei Guanlang focuses on supplying large volumes to agrochemical manufacturers. Its strategic location near raw‑material hubs reduces transportation costs and enables rapid replenishment cycles.

   Sustainability & Growth Initiatives: The firm has adopted a zero‑emission policy for its production lines and is investing in waste‑to‑energy projects.

   • High‑capacity batch reactors with automated safety protocols
   • ISO 14001 and REACH‑compliant operations
   • Collaborations with agribusinesses for new pesticide development
   • Implementation of energy‑efficient process controls

7. JRD Fluorochemicals Ltd. (India)

   Headquarters: Hyderabad, India
   Key Offering: Custom (2‑Chloroethyl)benzene synthesis for specialty chemicals

   JRD Fluorochemicals offers a portfolio of customized intermediates, supporting the development of advanced materials and high‑performance polymers. The company’s agile production strategy allows it to meet the evolving needs of the Indian chemical market.

   Sustainability & Growth Initiatives: JRD has launched a green‑chemistry program, incorporating catalytic halogenation and solvent‑recycling technologies.

   • Modular production units with rapid changeover capabilities
   • ISO 9001, ISO 14001, and REACH certifications
   • Strategic partnerships with polymer research institutes
   • Investment in renewable energy for plant operations

8. Enamine Ltd. (Ukraine)

   Headquarters: Kyiv, Ukraine
   Key Offering: Research‑grade (2‑Chloroethyl)benzene for medicinal chemistry

   Enamine supplies high‑purity intermediates to pharmaceutical R&D labs across Europe. Its focus on supporting early‑stage discovery projects has earned it a reputation for responsiveness and technical expertise.

   Sustainability & Growth Initiatives: The company has adopted solvent‑free synthesis routes and is exploring biobased catalysts to reduce environmental impact.

   • High‑purity production lines with rigorous quality control
   • ISO 9001 and GMP compliance
   • Collaborations with European research consortia
   • Continuous improvement program targeting waste reduction

9. Nacalai Tesque, Inc. (Japan)

   Headquarters: Osaka, Japan
   Key Offering: Specialty (2‑Chloroethyl)benzene for fine‑chemical intermediates

   Nacalai Tesque’s production facilities are equipped with advanced halogenation reactors capable of delivering ultra‑pure intermediates for fragrance and cosmetic applications. The company’s rigorous quality assurance processes align with international standards.

   Sustainability & Growth Initiatives: Nacalai is investing in renewable energy sources and has set a target to reduce greenhouse‑gas emissions by 20 % over the next decade.

   • High‑purity production with real‑time analytics
   • ISO 9001, ISO 14001, and REACH compliance
   • Partnerships with fragrance houses for novel scent development
   • Investment in energy‑efficient plant operations

Download FREE Sample Report

Get Full Report Here

Outlook

Over the next decade, the (2‑Chloroethyl)benzene market is poised to consolidate around a handful of high‑capacity, quality‑centric manufacturers. The dual forces of pharmaceutical innovation—particularly in personalized medicine—and agrochemical demand for next‑generation crop protection agents will sustain demand growth. Regulatory tightening around chlorinated intermediates will push operators toward greener production pathways, creating opportunities for firms that can demonstrate compliance and environmental stewardship.

Future Trends

• Adoption of continuous‑flow halogenation processes, improving safety and reducing batch variability.
• Expansion of bio‑based halogenation catalysts to lower chlorine consumption and mitigate environmental impact.
• Growing demand for ultra‑pure intermediates in the development of high‑value APIs and advanced polymers.
• Increased collaboration between chemical manufacturers and contract research organizations to accelerate new drug discovery.
• Strategic investments in digital process monitoring and AI‑driven quality control to enhance production efficiency.